Abstract:Abstract Dopamine agonist monotherapy is first line therapy in giant prolactinomas even when visual field defect is present. The costlier cabergoline is often preferred over bromocriptine due to higher efficacy and tolerability profile. Described herein combined cabergoline and bromocriptine therapy in 6 cases of giant prolactinomas. Retrospective records review of 6 patients with giant prolactinoma (3 males: M1-M3, 3 females: F1-F3) in a single tertiary centre was performed. Mean age at diagnosis: 29 years (range 17-39). Mean duration of follow up: 7 years (range 3-11). Headache and visual field defect were the presenting symptoms in all cases. Basal prolactin concentration: 100000 to 468851 mIU/L (<300 for male, <600 for female). Three patients have hypopituitarism at presentation, one after surgery and one remained eupitary 5 years after diagnosis. One developed late onset hypopituitarism 4 years after normalisation of prolactin levels. Three patients underwent debulking at presentation because of significant mass effects with obstructive hydrocephalus. In all patients cabergoline 1-1.5 mg/wk was started at diagnosis and gradually increased to 0.5 mg daily, aiming for normoprolactinemia. From May 2017 bromocriptine were given to these patients who continued to have hyperprolactinemia despite cabergoline 3.5-4mg/wk. Bromocriptine was commenced 1.25-5mg/day and gradually increased to 10 mg/day on top of cabergoline with careful monitoring of prolactin levels and side effects. Cabergoline was tapered down to 1.5-2mg/wk if prolactin levels remained stable between 2-3x normal while maintaining dose of bromocriptine. In M1, cabergoline was tapered off while maintaining bromocriptine 10mg/day with stable prolactin levels (~1000 mIU/L). In M2, normoprolactinemia was achieved after adding on bromocriptine and is currently on cabergoline 2mg/week and bromocriptine 10mg/day. In M3, whose prolactin were 4x normal value despite cabergoline 3.5mg/week, decreased 50% with bromocriptine 5 mg/day and remained stable when cabergoline reduced to 1.5mg/week. F1 had transphenoidal section twice due to failure of medical therapy. Her prolactin remained markedly elevated 10000-20000 mIU/L despite cabergoline 3.5 mg/week and bromocriptine 10mg/day, with persistent bitemporal hemianopia. F2 developed erythema nodosum after starting bromocriptine which was stopped and continued with cabergoline 1 mg/week. F3 showed partial response with 50% reduction in prolactin to 4485 mIU/L with bromocriptine 10 mg/day and cabergoline 1.5mg/week. In patients who underwent debulking, residual tumour remained unchanged. Two patients - tumour shrank 40% (F2) and 90% (M3) with medical therapy alone. In conclusion, adding on bromocriptine can be considered when high dose cabergoline is required for treatment of giant prolactinoma with careful monitoring. This reduces cabergoline dose which saves cost.

Combined treatment of invasive giant prolactinomas

Giant Prolactinomas: Outcomes of Multimodal Treatments for 42 Cases with Long-Term Follow-Up

Bromocriptine Treatment of Invasive Giant Prolactinomas Involving the Cavernous Sinus: Results of a Long-Term Follow Up.

Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist

[Treatment strategy of pituitary invasive prolactinomas]

Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup.

Cabergoline for the Treatment of Bromocriptine-Resistant Invasive Giant Prolactinomas

SAT-247 Use of Double Dopamine Agonists in Giant Prolactinomas: A Series of 6 Cases

Combined treatment of invasive giant prolactinomas (Report of 30 cases )

Study on treatment of prolactinomas:a report of 684 cases

Complete Shrinking of Mixed Growth Hormone and Prolactin-Secreting Pituitary Adenoma with Bromocriptine Therapy Alone

Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion

FRI318 A Case Of Mixed Growth Hormone And Prolactin-secreting Giant Pituitary Macroadenoma

Different Imaging Types and Surgical Treatment Strategies of Giant Nonfunctioning Pituitary Adenomas

Cabergoline Versus Bromocriptine for the Treatment of Giant Prolactinomas: A Quantitative and Systematic Review

Treatment of invasive giant prolactinomas with bromocriptine: results of long-term follow-up

A Comparative Study of Surgery and Drug Therapy for Adult Prolactinomas

Long-term Follow-up of 84 Patients With Giant Prolactinomas-A Swedish Nationwide Study

The role of surgical management for prolactin-secreting tumors in the era of dopaminergic agonists: An international multicenter report

Surgical treatment of giant pituitary adenomas via transsphenoidal approach

Endoscopic Endonasal Transcavernous Hemipituitary Transposition for Resection of Invasive Prolactinoma: 2-Dimensional Operative Video